Glancy Prongay & Murray LLP Commences Investigation on Behalf of Zimmer Biomet Holdings, Inc. Investors
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Zimmer Biomet Holdings, Inc.
(“Zimmer”) or the “Company”) (NYSE: ZBH) investors concerning the Company and its officers’ possible violations of federal securities laws.
Zimmer, together with its subsidiaries, provides musculoskeletal healthcare products and solutions in the Americas, Europe, the
Middle East, Africa, and the Asia Pacific.
On October 31, 2016 shares of Zimmer were down as much as 15% after the Company announced that it was lowering its full-year
forecast. While analysts had predicted revenues for 2016 being around $7.71 billion, Zimmer now expects revenues to be in the range
of $7.63 billion to $7.65 billion.
If you purchased Zimmer securities, have information or would like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at
310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and
number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Glancy Prongay & Murray LLP, Los Angeles/New York
Lesley Portnoy, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161101006351/en/